NCT00250471CompletedPhase 3
A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 900
- Primary Endpoint
- Efficacy: Improved Coronary Flow Reserve
Study Overview
Brief Summary
The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other cardiovascular complications who will undergo surgery to open up blocked arteries in the heart.
Detailed Description
Platelet inhibitor drugs
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Chest paing/discomfort that occurs at rest and lasts at least 10 minutes and have at least one of the following high-risk features:
- •elevated cardiac proteins in the blood (indicating acute coronary syndrome)
- •Be willing and able to give informed consent
Exclusion Criteria
- •uncontrolled hypertension
- •cardiac episode (heart attack) within the previous 24 hours before randomization into the trial
- •prior heart surgery (PCI) within the previous 2 weeks before randomizing in the trial
- •any electorcardogram (ECG) finding that make the Holter monitor for ischemia unable to read
Outcomes
Primary Outcomes
Efficacy: Improved Coronary Flow Reserve
Safety: TIMI major hemorrhage within 48 hours after randomizing in the trial or hosptial discharge, which ever occurs first.
Secondary Outcomes
- Duration of ischemia on continuous EKG monigoring through 24 hours after surgery.
- Composite death, heart attack and any occurance of ischemia based on the Holter monitor recording within 48 hours after randomizing into the trial
Investigators
Similar Trials
Completed
Phase 3
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCIMyocardial InfarctionNCT00093184The Medicines Company300
Completed
Phase 3
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of CirrhosisHepatitis B, ChronicHepatitisCirrhosisNCT00076336Novartis Pharmaceuticals232
Completed
Phase 2
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2Breast CancerNCT01593020M.D. Anderson Cancer Center54
Unknown
Phase 3
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV DrugsHIV InfectionsNCT00006208Triangle Pharmaceuticals
Completed
Phase 3
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial InfarctionMyocardial InfarctionNCT00433966Cardiovascular Research Foundation, New York3,602